These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 25189786)
1. Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. Miravitlles M; Huerta A; Fernández-Villar JA; Alcázar B; Villa G; Forné C; Cuesta M; Crespo C; García-Río F Health Qual Life Outcomes; 2014 Sep; 12():120. PubMed ID: 25189786 [TBL] [Abstract][Full Text] [Related]
2. Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease. Miravitlles M; Huerta A; Valle M; García-Sidro P; Forné C; Crespo C; López-Campos JL Int J Chron Obstruct Pulmon Dis; 2015; 10():367-77. PubMed ID: 25733826 [TBL] [Abstract][Full Text] [Related]
3. Geographic variations of the prevalence and distribution of COPD phenotypes in Spain: "the ESPIRAL-ES study". Alcázar-Navarrete B; Trigueros JA; Riesco JA; Campuzano A; Pérez J Int J Chron Obstruct Pulmon Dis; 2018; 13():1115-1124. PubMed ID: 29692606 [TBL] [Abstract][Full Text] [Related]
4. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study. Calle Rubio M; Casamor R; Miravitlles M Int J Chron Obstruct Pulmon Dis; 2017; 12():2373-2383. PubMed ID: 28848338 [TBL] [Abstract][Full Text] [Related]
5. Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study. Chai CS; Liam CK; Pang YK; Ng DL; Tan SB; Wong TS; Sia JE Int J Chron Obstruct Pulmon Dis; 2019; 14():565-573. PubMed ID: 30880946 [TBL] [Abstract][Full Text] [Related]
6. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446 [TBL] [Abstract][Full Text] [Related]
7. Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease. Bae E; Choi SE; Lee H; Shin G; Kang D BMC Pulm Med; 2020 Mar; 20(1):73. PubMed ID: 32293387 [TBL] [Abstract][Full Text] [Related]
8. Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease. Esquinas C; Ramon MA; Nuñez A; Molina J; Quintano JA; Roman-Rodríguez M; Naberan K; Llor C; Roncero C; Miravitlles M; Barrecheguren M Qual Life Res; 2020 Mar; 29(3):607-617. PubMed ID: 31673922 [TBL] [Abstract][Full Text] [Related]
9. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Solem CT; Sun SX; Sudharshan L; Macahilig C; Katyal M; Gao X Int J Chron Obstruct Pulmon Dis; 2013; 8():641-52. PubMed ID: 24376348 [TBL] [Abstract][Full Text] [Related]
10. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review. Wu JJ; Xu HR; Zhang YX; Li YX; Yu HY; Jiang LD; Wang CX; Han M BMC Pulm Med; 2020 Apr; 20(1):103. PubMed ID: 32326924 [TBL] [Abstract][Full Text] [Related]
11. Differences in cardiovascular risk and health-related quality of life in COPD patients according to clinical phenotype. Montiel AM; Ruiz-Esteban P; Del Río AD; Valdivielso P; Chaparro MÁS; Olveira C Sci Rep; 2024 Apr; 14(1):9687. PubMed ID: 38678074 [TBL] [Abstract][Full Text] [Related]
12. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Miravitlles M; Soler-Cataluña JJ; Calle M; Molina J; Almagro P; Quintano JA; Riesco JA; Trigueros JA; Piñera P; Simón A; López-Campos JL; Soriano JB; Ancochea J; Arch Bronconeumol; 2012 Jul; 48(7):247-57. PubMed ID: 22561012 [TBL] [Abstract][Full Text] [Related]
14. Clinical Features Of Women With COPD: Sex Differences In A Cross-Sectional Study In Spain ("The ESPIRAL-ES Study"). Trigueros JA; Riesco JA; Alcázar-Navarrete B; Campuzano A; Pérez J Int J Chron Obstruct Pulmon Dis; 2019; 14():2469-2478. PubMed ID: 31806956 [TBL] [Abstract][Full Text] [Related]
15. Active smoking and COPD phenotype: distribution and impact on prognostic factors. Riesco JA; Alcázar B; Trigueros JA; Campuzano A; Pérez J; Lorenzo JL Int J Chron Obstruct Pulmon Dis; 2017; 12():1989-1999. PubMed ID: 28740378 [TBL] [Abstract][Full Text] [Related]
16. [Estimating the prevalence of phenotypes in patients with pulmonary obstructive disease. ADEPOCLE study]. De Abajo Larriba AB; Méndez Rodríguez E; González-Gallego J; Capón Álvarez J; Díaz Rodríguez Á; Peleteiro Cobo B; Mahmoud Atoui O; De Abajo Olea S; Lumbreras González V; Martínez de Mandojana Hernández J Nutr Hosp; 2017 Feb; 34(1):180-185. PubMed ID: 28244790 [TBL] [Abstract][Full Text] [Related]
17. Impact of Clinical Factors on Generic and Disease-Specific Quality of Life in COPD and Asthma-COPD Overlap with Exacerbations. Lázár Z; Horváth A; Tomisa G; Tamási L; Müller V Pulm Med; 2020; 2020():6164343. PubMed ID: 32789027 [TBL] [Abstract][Full Text] [Related]
18. Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D. Szende A; Leidy NK; Ståhl E; Svensson K Qual Life Res; 2009 Mar; 18(2):267-72. PubMed ID: 19105049 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of chronic obstructive pulmonary disease phenotypes. One center prospective study. Said A; Esmail M; Abdel Naiem E; Zaki Z; Raouf R Adv Respir Med; 2021; 89(4):369-377. PubMed ID: 34494240 [TBL] [Abstract][Full Text] [Related]
20. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. Wacker ME; Jörres RA; Karch A; Wilke S; Heinrich J; Karrasch S; Koch A; Schulz H; Watz H; Leidl R; Vogelmeier C; Holle R; BMC Pulm Med; 2016 May; 16(1):70. PubMed ID: 27160582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]